Impact of collateral flow on cost-effectiveness of endovascular thrombectomy.


Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 17 12 2021
accepted: 07 02 2022
pubmed: 11 5 2022
medline: 6 12 2022
entrez: 10 5 2022
Statut: epublish

Résumé

Acute ischemic stroke patients with large-vessel occlusion and good collateral blood flow have significantly better outcomes than patients with poor collateral circulation. The purpose of this study was to evaluate the cost-effectiveness of endovascular thrombectomy (EVT) based on collateral status and, in particular, to analyze its effectiveness in ischemic stroke patients with poor collaterals. A decision analysis study was performed with Markov modeling to estimate the lifetime quality-adjusted life-years (QALYs) and associated costs of EVT based on collateral status. The study was performed over a lifetime horizon with a societal perspective in the US setting. Base-case analysis was done for good, intermediate, and poor collateral status. One-way, two-way, and probabilistic sensitivity analyses were performed. EVT resulted in greater effectiveness of treatment compared to no EVT/medical therapy (2.56 QALYs in patients with good collaterals, 1.88 QALYs in those with intermediate collaterals, and 1.79 QALYs in patients with poor collaterals), which was equivalent to 1050, 771, and 734 days, respectively, in a health state characterized by a modified Rankin Scale (mRS) score of 0-2. EVT also resulted in lower costs in patients with good and intermediate collaterals. For patients with poor collateral status, the EVT strategy had higher effectiveness and higher costs, with an incremental cost-effectiveness ratio (ICER) of $44,326/QALY. EVT was more cost-effective as long as it had better outcomes in absolute numbers in at least 4%-8% more patients than medical management. EVT treatment in the early time window for good outcome after ischemic stroke is cost-effective irrespective of the quality of collateral circulation, and patients should not be excluded from thrombectomy solely on the basis of collateral status. Despite relatively lower benefits of EVT in patients with poor collaterals, even smaller differences in better outcomes have significant long-term financial implications that make EVT cost-effective.

Identifiants

pubmed: 35535841
doi: 10.3171/2022.2.JNS212887
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1801-1810

Auteurs

Mihir Khunte (M)

1Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.

Xiao Wu (X)

2Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Emily W Avery (EW)

1Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.

Dheeraj Gandhi (D)

3Department of Radiology, University of Maryland Medical Center, Baltimore, Maryland.

Seyedmehdi Payabvash (S)

1Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.

Charles Matouk (C)

1Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
4Department of Neurosurgery, Yale University, New Haven, Connecticut.

Jeremy J Heit (JJ)

5Department of Radiology.
6Department of Neurosurgery, and.

Max Wintermark (M)

5Department of Radiology.

Gregory W Albers (GW)

6Department of Neurosurgery, and.
7Department of Neurology, Stanford University, Stanford, California; and.

Pina Sanelli (P)

8Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Long Island, New York.

Ajay Malhotra (A)

1Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH